In a world where luxury is increasingly measured not only by what we possess, but by the quality of our lives, one organization is reshaping what it means to live well. M42, a global health company headquartered in Abu Dhabi, is quietly leading one of the most ambitious transformations in global health, blending world-class clinical care with artificial intelligence (AI), genomics and advanced technologies to make healthcare more personalized, more proactive and more accessible, and elevate health in ways once reserved for the future.
M42 was created when Mubadala Health and G42 Healthcare came together, bringing more than 20,000 caregivers, clinicians, scientists and technologists under one mission: to deliver the best possible care to individuals, families and communities. Its network spans more than 480 healthcare facilities across 27 countries, serving millions of patients each year from expectant mothers and families to travellers seeking personalized medical experiences. This global footprint supports comprehensive care delivery from acute and complex specialist services to renal care.
Yet what sets M42 apart is not just scale and expertise, but connecting everyday care with cutting-edge science and advanced technology for the ultimate expression of luxury, longevity and personal empowerment.
At a time when discerning individuals curate every detail of their lives from bespoke travel to tailored wellness programs, M42 is offering a new frontier of personalization: precision health. Its integrated platforms combine genomics, population-scale clinical and genomic datasets, advanced analytics, multimodal AI and next-generation digital infrastructure. The result? Care that is personalized rather than standardized; preventive rather than sickness-driven; and, predictive rather than reactive. These capabilities enable personalized interventions, risk stratification, early detection and predictive insights, as healthcare shifts more toward prevention-first models of care.
A cornerstone of M42’s impact is operating the Emirati Genome Program (EGP), in partnership with the Department of Health – Abu Dhabi. With over 850,000 genomes sequenced, EGP is generating insights that allow individuals to understand their future health risks and take steps today to prevent disease tomorrow. This is longevity, elevated.
Through this work, M42 is identifying risks early, empowering individuals with personalized and preventive care and reducing the long-term disease burden. Already, breakthroughs in preventive treatment are being made, helping patients avoid diseases, such as cancer, altogether. M42’s Omics Centre of Excellence, the largest in the world outside the U.S., drives these large-scale sequencing efforts to create one of the world’s largest and most diverse genomic datasets. For the global luxury consumer, this represents a new horizon: a world where medicine adapts to the individual rather than the other way around.
The ambition doesn’t end with genomics. Complementing EGP is the Abu Dhabi Biobank, also developed in collaboration with the Department of Health – Abu Dhabi. As one of the world’s most advanced repositories of biological samples, storing up to 100,000 cord-blood units and millions of biomaterials, this facililty is supporting biomedical research, stem-cell therapies, disease understanding, clinical trials and data-driven discovery. Together, the Abu Dhabi Biobank and EGP form the backbone of the UAE’s genomics, precision-health and life sciences ecosystem.
M42’s partnerships with leading pharmaceutical and biotechnology companies, including AstraZeneca and GEMMABio Therapeutics, further accelerate the development of cutting-edge therapies and personalised interventions for rare diseases, inherited conditions and complex health challenges.
Today, M42’s capabilities span the full healthcare innovation spectrum: state-of-the-art clinical services, genomics and multi-omics, biobanking, digital health, applied AI, research and translational science. While rooted in the UAE, M42’s impact is deeply global, acting as a bridge between regional health systems and the international life sciences excellence.
M42 stands at the forefront of the global healthcare transformation. It represents something profound: a glimpse of the future of health. is luxury’s next frontier: health that is personal, predictive and purposefully designed around the individual. And, M42 is leading the world there.
By Carla Branco
INFO: https://m42.ae